Table 1.

Baseline characteristics

	Chemotherapy (n = 41)	Decitabine priming (n = 40)	p value
Sex, n (%)			0.722
Male	23 (56.1%)	24 (60.0%)
Female	18 (43.9%)	16 (40.0%)
Median age
(IQR; years)	55 (41–61)	55 (39–62)	0.860
Neutrophil count
(IQR; ×109/L)	1.5 (1.1–2.9)	1.5 (1.1–3.4)	0.709
Hemoglobin level
(IQR; g/L)	73 (60–86)	75 (61–95)	0.385
Platelet count
(IQR; ×109/L)	51 (34–85)	52 (33–86)	0.745
WHO classification, n (%)			0.152
RAEB-1	14 (34.1%)	8 (20.0%)
RAEB-2	27 (65.9%)	32 (80.0%)
Cytogenetic risk group, n (%)			0.541
Favorable	23 (56.1%)	28 (70.0%)
Intermediate	9 (22.0%)	7 (17.5%)
Unfavorable	5 (12.2%)	2 (5.0%)
Unknown	4 (9.7%)	3 (7.5%)
IPSS risk, n (%)			0.364
Intermediate-1	9 (22.0%)	7 (17.5%)
Intermediate-2	18 (43.9%)	25 (62.5%)
High	10 (24.4%)	5 (12.5%)
Unknown	4 (9.7%)	3 (7.5%)